BMJ Open  Measurement of Exercise Tolerance before Surgery (METS) study: a protocol for an international multicentre prospective cohort study of cardiopulmonary exercise testing prior to major non-cardiac surgery

Duminda N Wijeysundera,1 Rupert M Pearse,2 Mark A Shulman,3 Tom E F Abbott,2 Elizabeth Torres,4 Bernard L Croal,5 John T Granton,6 Kevin E Thorpe,7 Michael P W Grocott,8 Catherine Farrington,9 Paul S Myles,3 Brian H Cuthbertson,9 on behalf of the METS Study Investigators

ABSTRACT

Introduction: Preoperative functional capacity is considered an important risk factor for cardiovascular and other complications of major non-cardiac surgery. Nonetheless, the usual approach for estimating preoperative functional capacity, namely doctors’ subjective assessment, may not accurately predict postoperative morbidity or mortality. 3 possible alternatives are cardiopulmonary exercise testing; the Duke Activity Status Index, a standardised questionnaire for estimating functional capacity; and the serum concentration of N-terminal pro-B-type natriuretic peptide (NT pro-BNP), a biomarker for heart failure and cardiac ischaemia.

Methods and analysis: The Measurement of Exercise Tolerance before Surgery (METS) Study is a multicentre prospective cohort study of patients undergoing major elective non-cardiac surgery at 25 participating study sites in Australia, Canada, New Zealand and the UK. We aim to recruit 1723 participants. Prior to surgery, participants undergo symptom-limited cardiopulmonary exercise testing on a cycle ergometer, complete the Duke Activity Status Index questionnaire, undergo blood sampling to measure serum NT pro-BNP concentration and have their functional capacity subjectively assessed by their responsible doctors. Participants are followed for 1 year after surgery to assess vital status, postoperative complications and general health utilities. The primary outcome is all-cause death or non-fatal myocardial infarction within 30 days after surgery, and the secondary outcome is all-cause death within 1 year after surgery. Both receiver-operating-characteristic curve methods and risk reclassification table methods will be used to compare the prognostic accuracy of preoperative subjective assessment, peak oxygen consumption during cardiopulmonary exercise testing, Duke Activity Status Index scores and serum NT pro-BNP concentration.

Strengths and limitations of this study

- A large generalisable sample of 1723 participants at multiple centres worldwide will be used to estimate the prognostic accuracy of cardiopulmonary exercise testing, the Duke Activity Status Index and the serum concentration of N-terminal pro-B-type natriuretic peptide.
- The study involves detailed prospective follow-up after surgery to ascertain survival, major complications and general health utilities.
- Participants, healthcare personnel and outcome adjudicators are blinded to cardiopulmonary exercise testing results, Duke Activity Status Index scores and serum N-terminal pro-B-type natriuretic peptide concentration, thereby facilitating unbiased estimates of their prognostic accuracy.
- An important potential limitation is selection bias introduced by individuals who meet eligibility criteria, are theoretically capable of exercising, but decline to participate in a research study of exercise testing. Such non-participants may be systematically different due to possible higher likelihood of having other markers of poor health (eg, smoking).

Ethics and dissemination: The METS Study has received research ethics board approval at all sites. Participant recruitment began in March 2013, and 1-year follow-up is expected to finish in 2016. Publication of the results of the METS Study is anticipated to occur in 2017.

INTRODUCTION

More than 300 million individuals undergo major surgery worldwide every year, and...
many are at risk for postoperative cardiovascular complications.\(^1\)\(^2\) Clinical practice guidelines recommend preoperative risk stratification as a component of any strategy to prevent these complications.\(^3\) Risk-stratification algorithms proposed by several international guidelines emphasise the assessment of preoperative fitness or functional capacity.\(^4\)\(^5\) For example, the current American College of Cardiology and American Heart Association guidelines recommend that patients be allowed to proceed directly to elective major non-cardiac surgery if they are deemed capable of more than four metabolic equivalents of activity without symptoms.\(^6\) Preoperative functional capacity is also a versatile measure of perioperative risk since it may stratify risk for non-cardiovascular complications such as pneumonia, respiratory failure and infection.\(^5\)\(^6\)\(^7\)\(^8\)

The current standard of care for assessing preoperative functional capacity involves a doctor making a subjective estimate after interviewing the patient. Previous studies highlight potential limitations with this approach, including poor accuracy when predicting death or complications after non-cardiac surgery,\(^9\)\(^10\)\(^11\) as well as poor agreement with validated measures of functional capacity.\(^12\) These limitations point to the need for more accurate alternatives to assess preoperative functional capacity and, in turn, surgical outcomes. Three potential options are cardiopulmonary exercise testing (CPET), which is often considered to be the ‘gold standard’ non-invasive assessment of functional capacity; the Duke Activity Status Index (DASI),\(^13\) which is a standardised questionnaire with demonstrated correlation to gold standard measures of functional capacity; and the serum concentration of NT pro-BNP, which is biomarker for heart failure or cardiac ischaemia.

CPET requires patients to undergo symptom-limited incremental exercise on a bicycle or treadmill for 8–12 min while undergoing continuous spirometry. Indices of cardiorespiratory performance are simultaneously measured, with the most common being peak oxygen consumption (VO\(_2\) peak) and anaerobic threshold (AT). Recent systematic reviews and individual studies largely support preoperative CPET as a predictor of complications after surgery,\(^14\)\(^15\)\(^16\) but acknowledge important limitations. For example, many prior studies have important methodological problems. Specifically, very few studies blinded caregivers or outcome adjudicators to CPET results,\(^17\)\(^18\)\(^19\) thereby potentially biasing estimates of prognostic accuracy in the vast majority of previous studies.\(^20\)

In addition, many studies have limited generalisability due to small sample sizes and single-centre designs. Thus, despite the theoretical promise of CPET in the perioperative setting, higher quality evidence remains needed to confirm its prognostic accuracy, identify patients who warrant this expensive and specialised test, and provide a robust argument for its wider implementation.

The DASI is a 12-item self-administered questionnaire enquiring about activities of daily living. It has construct and criterion validity as a measure of functional capacity in surgical patients.\(^21\)\(^22\) No large study has evaluated the prognostic accuracy of a preoperative DASI score for predicting outcomes after surgery.

While no blood test can quantify functional capacity, serum concentration of NT pro-BNP may indirectly fulfil this role by serving as an integrated marker of cardiac dysfunction, including myocardial stretch and ischaemia.\(^23\)\(^24\) Emerging data, which include several individual studies from our group as well as meta-analyses,\(^25\)\(^26\)\(^27\)\(^28\)\(^29\)\(^30\)\(^31\) have found preoperative NT pro-BNP concentrations to have reasonable prognostic accuracy in predicting death and cardiac complications after non-cardiac surgery.

To help develop improved methods to measure preoperative functional capacity and incorporate it into overall surgical risk assessment, we are conducting the Measurement of Exercise Tolerance before Surgery (METS) Study. The main objectives of this multicentre prospective cohort study are presented below.

**Primary objective**
To compare preoperative CPET to subjective assessment for predicting death within 1 year after major elective non-cardiac surgery.

**Secondary objectives**
1. To compare CPET to subjective assessment for predicting death within 1 year after major elective non-cardiac surgery.
2. To compare preoperative DASI, NT pro-BNP, CPET and subjective assessment for predicting death or non-fatal MI within 30 days after non-cardiac surgery.
3. To compare preoperative DASI, NT pro-BNP, CPET and subjective assessment for predicting death within 1 year after major elective non-cardiac surgery.

**METHODS AND ANALYSIS**

**Study design**
The METS Study is a multinational prospective cohort study of 1723 patients undergoing major elective non-cardiac surgery at participating centres in Australia, Canada, New Zealand and the UK. The overall study design is outlined in figure 1.

**Participant eligibility criteria**
Potential participants are recruited from the preoperative assessment clinics or surgical wards of participating sites. To be eligible to participate in the METS Study, individuals must be aged 40 years or older, and scheduled to undergo elective non-cardiac surgery under general and/or regional anaesthesia with a minimum of an overnight hospital stay for medical reasons. In addition, they must have one or more clinical risk factors for perioperative cardiac complications or coronary artery disease (table 1). Exclusion criteria are presented
Patients (aged 40 years or older) awaiting major elective non-cardiac surgery (anticipated overnight stay or longer in hospital) - screened in preoperative assessment clinic or wards

**Inclusion Criteria**
Informed consent and meeting 1 or more of the 10 criteria below:
1. History of coronary artery disease
2. History of heart failure
3. History of cerebrovascular disease
4. History of diabetes mellitus
5. Estimated glomerular filtration rate less than 60 mL/min/1.73 m²
6. History of peripheral arterial disease
7. History of hypertension
8. History of smoking in previous 1 year
9. Age of 70 years or more
10. Intermediate-to-high risk surgical procedure

**Preoperative Assessment of Functional Capacity**
1. Physician’s subjective assessment of functional capacity
2. Duke Activity Status Index (scored from 0 to 58.2 points)
3. Plasma NT pro-BNP concentration
4. CPET using cycle ergometer - peak oxygen consumption (VO₂ peak) is measured

**Surgery**
All clinicians and outcome assessors with be blinded to CPET, DASI and NT pro-BNP results.

**In-Hospital Surveillance**
1. Daily troponin measurements up to postoperative day 3
2. Daily ECG up to postoperative day 3

**30-Day Outcome**
All-cause death or non-fatal myocardial infarction

**1-Year Outcome**
Death

**Figure 1** Overall design of the METS Study. CPET, cardiopulmonary exercise test; DASI, Duke Activity Status Index; METS, Measurement of Exercise Tolerance before Surgery; NT pro-BNP, N-terminal pro-B-type natriuretic peptide; VO₂, oxygen consumption.

on box 1 and table 2. All participants provide informed consent at time of recruitment to the study.

**Preoperative cardiopulmonary exercise testing**
During the period from study recruitment to 1 day before surgery, participants undergo symptom-limited incremental CPET on a computer-controlled, electromagnetically braked cycle ergometer, under physician supervision and in accordance with published guidelines. Prior to CPET, each participant performs spirometry with forced inspiratory and expiratory flow volume loops. The subsequent incremental exercise test takes 8–
Participants exercise until they reach their limit of tolerance (ie, unable to pedal at 60 revolutions per minute despite encouragement), stop for non-cardiopulmonary reasons or are instructed to stop based on safety-based termination criteria. Reasons for termination are documented for all tests. Participants undergo breath-by-breath measurement of minute ventilation, oxygen uptake and carbon dioxide production from expired gas during the exercise test. In addition, heart rate, blood pressure, three-lead ECG, arterial oxygen saturation and rating of perceived exertion (modified Borg scale) are measured. After the exercise test is stopped, participants continue to pedal for a 5 min recovery period, during which the work intensity is reduced to 20 W. During this recovery period, monitoring of heart rate, blood pressure, ECG, oxygen consumption and carbon dioxide production is continued.

The site investigator at each participating CPET centre determines VO$_2$ peak and AT using full-page graphs of the plotted local CPET data. The VO$_2$ peak is defined as the average oxygen consumption during the last 20 s of the incremental phase of exercise before attaining the limit of tolerance. The AT is determined using the modified V-Slope method. If the AT is indeterminate based on this method alone, the ventilatory equivalent method and excess carbon dioxide method are applied sequentially until the AT is either measured or classified as indeterminate. Participants, clinicians and outcome adjudicators are blinded to all CPET results, except if myocardial ischaemia or significant new arrhythmias occur during exercise, or spirometry shows previously undiagnosed very severe obstructive lung disease (forced expiratory volume in 1 s less than 30% predicted). In these cases, clinicians are informed

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intermediate-to-high risk surgery</td>
<td>Intraperitoneal, intrathoracic or major vascular (suprainguinal or lower extremity vascular) procedures</td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td>History of angina; myocardial infarction; positive exercise, nuclear or echocardiographic stress test; resting wall motion abnormalities on echocardiogram; coronary angiography with evidence of ≥50% vessel stenosis; or ECG with pathological Q-waves in two contiguous leads</td>
</tr>
<tr>
<td>Heart failure</td>
<td>History of heart failure or diagnostic chest X-ray (ie, pulmonary vascular redistribution or pulmonary oedema)</td>
</tr>
<tr>
<td>Cerebrovascular disease</td>
<td>History of stroke or transient ischaemic attack; or imaging (CT or MRI) evidence of previous stroke</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>Requirement for insulin or oral hypoglycaemic therapy</td>
</tr>
<tr>
<td>Preoperative renal insufficiency</td>
<td>Requirement for renal replacement therapy before surgery, or estimated glomerular filtration rate less than 60 mL/min/1.73 m$^2$</td>
</tr>
<tr>
<td>Peripheral arterial disease</td>
<td>History of peripheral arterial disease; ischaemic intermittent claudication; rest pain; lower limb revascularisation procedure; peripheral arterial obstruction of ≥50% luminal diameter; or resting ankle/arm systolic blood pressure ratio ≤0.90</td>
</tr>
<tr>
<td>Hypertension</td>
<td>Physician diagnosis of hypertension</td>
</tr>
<tr>
<td>Smoker</td>
<td>History of smoking within 1 year before surgery</td>
</tr>
<tr>
<td>Advanced age</td>
<td>70 years or older</td>
</tr>
</tbody>
</table>

*One or more of these risk factors must be present to meet the study eligibility criteria.
†Estimated using the MDRD Study equation.

MDRD, Modification of Diet in Renal Disease; METS, Measurement of Exercise Tolerance before Surgery.
of these specific findings, but not the VO₂ peak or AT values.

Other estimates of preoperative functional capacity
Each participant undergoes three other assessments of preoperative functional capacity. Subjective assessment of the participant’s functional capacity is performed either by the attending doctor in the preoperative assessment clinic on the day of recruitment, or by the attending anaesthesiologist on the day of surgery. This estimate is categorised as poor (less than 4 metabolic equivalents), moderate (4–10 metabolic equivalents) or good (more than 10 metabolic equivalents). In addition, the DASI questionnaire is completed on the day of recruitment. At any point between study recruitment and initiation of surgery, a blood sample is drawn to measure the serum concentration of NT pro-BNP. These samples are initially stored at −70°C to −80°C in each study site, and then sent for analysis at the core study laboratory, the Clinical Biochemistry Laboratory at the Aberdeen Royal Infirmary (Aberdeen, UK). The NT pro-BNP samples are analysed in batches using the Siemens Vista immunoassay analyser (Siemens Healthcare Diagnostics Ltd, Frimley, UK). Clinicians and outcome adjudicators are blinded to DASI and NT pro-BNP results, while participants are blinded to NT pro-BNP results.

Follow-up procedures
Research personnel follow the study participants daily throughout their hospital stay. While participants remain in hospital, follow-up procedures includes performance of ECGs, the Postoperative Morbidity Survey and blood sampling to measure troponin and creatinine concentrations. The ECGs and blood sampling are performed daily for the first 3 days after surgery, while the Postoperative Morbidity Survey is administered on the third and fifth days after surgery. The specific troponin assays used are the preferred assays at each participating site. After hospital discharge, participants are contacted again at 30 days and 1 year after surgery to ascertain study-related outcomes, including vital status and health utilities measured by the EuroQol EQ-5D.

Outcome measures
The primary outcome is all-cause death or non-fatal MI within 30 days after surgery. All potential MI events are centrally adjudicated based on consensus-based definitions (table 3) by an Outcome Adjudication Committee that is blinded to all CPET, DASI and NT pro-BNP results. The secondary outcome is all-cause death within 1 year after surgery. Postoperative follow-up also includes ascertainment of other clinical events (table 3) to help further explain any differing survival associated with preoperative functional capacity.

Statistical analysis
Since the METS Study compares several tests for predicting postoperative risk, the main statistical analyses will only include individuals who undergo their planned surgeries. Nonetheless, characteristics and outcomes of

---

**Table 2** Definitions of specific exclusion criteria in the METS Study

| Active cardiac conditions⁵⁹ | Acute coronary syndrome: myocardial infarction within prior 30 days, unstable angina, or severe angina (Canadian Cardiovascular Society class III or IV)  
Decompensated heart failure (New York Heart Association functional Class IV), new onset heart failure, or worsening heart failure  
Significant arrhythmias: atrioventricular heart block (high grade, Mobitz II, third-degree); symptomatic ventricular arrhythmias; supraventricular arrhythmias with uncontrolled ventricular rate (ie, >100 bpm at rest); symptomatic bradycardia; or newly recognised ventricular tachycardia  
Severe valvular disease: severe aortic stenosis (mean pressure gradient >40 mm Hg, aortic valve area <1.0 cm² or symptomatic aortic stenosis); or symptomatic mitral stenosis (progressive dyspnoea on exertion, exertional presyncope or heart failure) |
| Absolute contraindications to CPET³⁰ | Recent acute myocardial infarction (3–5 days) or unstable angina  
Uncontrolled arrhythmias causing symptoms or haemodynamic compromise  
Syncpe  
Active endocarditis  
Acute myocarditis or pericarditis  
Symptomatic severe aortic stenosis  
Uncontrolled heart failure or pulmonary oedema  
Acute pulmonary embolus or pulmonary infarction  
Thrombosis of lower extremities  
Suspected dissecting aneurysm  
Uncontrolled asthma or respiratory failure  
Oxygen saturation at rest less than 85%  
Acute non-cardiopulmonary disorder that may affect exercise performance or be aggravated by exercise (ie, infection, renal failure, thyrotoxicosis)  
Mental impairment leading to inability to cooperate |

CPET, cardiopulmonary exercise testing; METS, Measurement of Exercise Tolerance before Surgery.
<table>
<thead>
<tr>
<th>Outcome</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myocardial infarction</td>
<td>An elevation in serum troponin that both ▶ Exceeds the 99th centile of the normal reference population ▶ Exceeds the threshold at which the coefficient of variation for the assay is 10% At least one of the following must be present: ▶ Clinical symptoms of ischaemia ▶ Typical ECG changes of ischaemia ▶ New pathological Q-waves on ECG ▶ Coronary artery intervention ▶ New (or presumed new) changes on echocardiography or radionuclide imaging</td>
</tr>
<tr>
<td>Myocardial injury</td>
<td>An elevation in serum troponin that both ▶ Exceeds the 99th centile of the normal reference population ▶ Exceeds the threshold at which the coefficient of variation for the assay is 10%</td>
</tr>
<tr>
<td>Non-fatal cardiac arrest</td>
<td>Successful resuscitation from documented (or presumed) ventricular fibrillation, sustained ventricular tachycardia, asystole, or pulseless electrical activity</td>
</tr>
<tr>
<td>Heart failure</td>
<td>Presence of both ▶ Clinical findings (ie, elevated jugular venous pressure, respiratory rales, crepitations, S3 heart sounds) ▶ Radiological findings (ie, vascular redistribution, interstitial or frank pulmonary oedema) New focal neurological deficit, suspected to vascular in origin, with signs/symptoms lasting ≥24 h</td>
</tr>
<tr>
<td>Stroke</td>
<td>New focal neurological deficit that lasts less than 24 h and is thought to be vascular in origin</td>
</tr>
<tr>
<td>Transient ischaemic attack</td>
<td>New focal neurological deficit, suspected to vascular in origin with signs/symptoms lasting ≥24 h and is thought to be vascular in origin</td>
</tr>
<tr>
<td>Respiratory failure</td>
<td>Need for tracheal intubation and mechanical ventilation after patient has completed surgery, been successful extubated, and breathing spontaneously for &gt;1 h</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>Documented hypoxaemia (PaO₂/FiO₂ ratio ≤250 mm Hg) or fever (temperature &gt;37.5°C) with either: 1. Rales or dullness to percussion on chest examination and any of (i) new onset of purulent sputum or change in sputum character; (ii) organism isolated from blood culture; or (iii) pathogen isolated from transtracheal aspirate, bronchial brushing or biopsy 2. New or progressive infiltrate, consolidation, cavitation or pleural effusion on chest radiograph and any of (1) criteria i, ii or iii above; (2) detection of virus or viral antigen in respiratory secretions; (3) diagnostic antibody titres; or (4) histopathological evidence of pneumonia</td>
</tr>
<tr>
<td>Surgical site infection</td>
<td>Physician diagnosis of surgical site infection during: ▶ Index hospitalisation ▶ Outpatient visit, hospital readmission or emergency room visit within 30 days after index surgery</td>
</tr>
<tr>
<td>Deep venous thrombosis</td>
<td>Any of the following during index hospitalisation: 1. Persistent intraluminal filling defect on contrast venography 2. One or more non-compressible venous segments on B mode compression ultrasonography 3. Clearly defined intraluminal filling defect on contrast-enhanced CT</td>
</tr>
<tr>
<td>Pulmonary embolism</td>
<td>Any of the following during index hospitalisation: 1. High probability ventilation/perfusion lung scan 2. Intraluminal filling defect of segmental or larger artery on a helical CT scan 3. Intraluminal filling defect on pulmonary angiography 4. A positive diagnostic test for DVT (eg, positive compression ultrasound) plus low or intermediate probability ventilation/perfusion lung scan, or non-diagnostic (subsegmental defects or technically inadequate study) helical CT scan</td>
</tr>
<tr>
<td>Significant bleeding</td>
<td>Blood loss with any of the following characteristics: 1. Results in drop in haemoglobin of 30 g/L or more 2. Leads to red cell transfusion or re-operation 3. Is considered to the cause of death</td>
</tr>
<tr>
<td>Postoperative complications*</td>
<td>Severity of complications are classified (based on most severe events during the index hospitalisation) as: 1. None 2. Mild: only temporary harm that does not require clinical treatment 3. Moderate: required clinical treatment but without significantly prolonged hospital stay. Does not usually result in permanent harm and where this does occur, the harm does not cause functional limitation 4. Severe—requires clinical treatment and results in significant prolongation of hospital stay and/or permanent functional limitation</td>
</tr>
</tbody>
</table>

Continued
individuals who do not undergo their planned surgeries will still be captured and described separately. Two complementary analyses are planned to account for participants who are not able to exercise enough to provide a valid measurement of VO2 peak. Analyses will be performed only after completion of 1-year follow-up for all recruited participants.

The primary analysis includes individuals who successfully complete CPET by reaching their limit of tolerance with a valid measurement of VO2 peak. Two sets of logistic regression models will be used to separately model the risks of (1) 30-day non-fatal MI or death and (2) 1-year death. We will first include only baseline clinical data (ie, risk factors in the Revised Cardiac Risk Index), and then, in sequential fashion, add in subjective assessment, followed by VO2 peak to the model. The statistical significance of prognostic information from the additional predictors will be assessed based on the increase in log likelihood of the ‘larger’ model. We will also determine the area under the receiver-operating-characteristic (ROC) curve of models with successively more predictors, as well as models with only the individual exposure of interest (eg, subjective assessment alone, or VO2 peak alone). The difference in overall prognostic information between models will be assessed by comparing the area under the curve (AUC) of two ROC curves. We have based our sample size calculation on the AUC of ROC curves for CPET versus subjective assessment with respect to predicting 30-day non-fatal MI or death. Assuming an outcome event rate of 8%, a poor-to-moderate AUC of 0.65 for subjective assessment, a moderately good AUC of 0.75 for VO2 peak, and a conservative estimated correlation of 0.5 between VO2 peak and subjective assessment, a sample size of 1180 participants has 90% power to detect this clinically relevant difference in AUC values (two-sided α of 0.05). If the outcome event rate is instead 6%, this sample size has 81% power to detect the same difference. Based on studies that conducted systematic postoperative surveillance of intermediate-to-high risk patients undergoing non-cardiac surgery, we anticipate the rate of 30-day non-fatal MI or death to be 6–9%. This sample size of 1180 applies to the primary analysis, which is restricted to individuals who undergo their planned non-cardiac surgery and complete CPET with a valid measurement of VO2 peak. Thus, this analysis does not necessarily include all individuals who consent to participate in the METS Study. For example, it does not include individuals who cannot exercise sufficiently for a valid measurement of VO2 peak, or fail to attend their CPET session due to unexpected rescheduling of planned surgeries. To account for up to 10% of recruited participants not being eligible for inclusion in the primary analysis, the overall sample size was increased to 1312.

After recruiting half of the original planned sample size, this sample size calculation was re-evaluated based on two factors identified in the accumulating study data. First, we found that about 20% of participants did not either successfully complete CPET or undergo their planned surgeries. Second, the event rate for the primary outcome was approximately 5%. Based on this information, the overall sample size was increased to 1723 participants to account for up to 20% of recruited individuals not being eligible for the primary analysis, and a primary outcome event rate of 5%, while retaining the power of 80%. Importantly, no data on the principal exposures (ie, CPET results, DASI scores, NT pro-BNP concentration) were considered during this sample size re-estimation.

### Sample size calculation

The sample size calculation is based on comparing the AUC of ROC curves for CPET versus subjective assessment with respect to predicting 30-day non-fatal MI or death. Assuming an outcome event rate of 8%, a poor-to-moderate AUC of 0.65 for subjective assessment, a moderately good AUC of 0.75 for VO2 peak, and a conservative estimated correlation of 0.5 between VO2 peak and subjective assessment, a sample size of 1180 participants has 90% power to detect this clinically relevant difference in AUC values (two-sided α of 0.05). If the outcome event rate is instead 6%, this sample size has 81% power to detect the same difference. Based on studies that conducted systematic postoperative surveillance of intermediate-to-high risk patients undergoing non-cardiac surgery, we anticipate the rate of 30-day non-fatal MI or death to be 6–9%. This sample size of 1180 applies to the primary analysis, which is restricted to individuals who undergo their planned non-cardiac surgery and complete CPET with a valid measurement of VO2 peak. Thus, this analysis does not necessarily include all individuals who consent to participate in the METS Study. For example, it does not include individuals who cannot exercise sufficiently for a valid measurement of VO2 peak, or fail to attend their CPET session due to unexpected rescheduling of planned surgeries. To account for up to 10% of recruited participants not being eligible for inclusion in the primary analysis, the overall sample size was increased to 1312.

After recruiting half of the original planned sample size, this sample size calculation was re-evaluated based on two factors identified in the accumulating study data. First, we found that about 20% of participants did not either successfully complete CPET or undergo their planned surgeries. Second, the event rate for the primary outcome was approximately 5%. Based on this information, the overall sample size was increased to 1723 participants to account for up to 20% of recruited individuals not being eligible for the primary analysis, and a primary outcome event rate of 5%, while retaining the power of 80%. Importantly, no data on the principal exposures (ie, CPET results, DASI scores, NT pro-BNP concentration) were considered during this sample size re-estimation.
Study management and funding
The Applied Health Research Centre at St Michael’s Hospital (Toronto, Ontario, Canada) is responsible for the overall international coordination of the METS Study. Two national coordinating centres also help liaise with local investigators in specific countries, namely the Royal London Hospital (London, UK) for the UK, and the Alfred Hospital (Melbourne, Victoria, Australia) for Australia and New Zealand. The study investigators participating in the METS Study, as well as their respective roles, are listed in the online supplementary data appendix. All study data are captured with electronic case record forms on a secure web-based database that was developed using Medidata RAVE (Medidata Solutions Inc, New York, New York, USA). The METS Study is funded by peer-reviewed grants from the Canadian Institutes of Health Research, Heart and Stroke Foundation of Canada, Ontario Ministry of Health and Long-Term Care, National Institute of Academic Anaesthesia, UK Clinical Research Network, Australian and New Zealand College of Anaesthetists, and Monash University (Melbourne, Victoria, Australia).

Study status
Participant recruitment to the METS Study was started in March 2013. The study involves 25 participating centres in Australia, Canada, New Zealand and the UK. Completion of 1-year follow-up period is anticipated for late 2016.

Substudies
We have developed a formal process for investigators within the research group to propose, design and lead substudies based on the data collected from this large international cohort of patients undergoing major elective non-cardiac surgery. Three substudies have already been prespecified. The first substudy will evaluate the prognostic accuracy of AT as determined by site investigators at each participating CPET centre. The second substudy will evaluate the prognostic accuracy of VO2 peak and AT measurements that are centrally adjudicated by a panel of three CPET experts. These experts will remain blinded to initial assessments made by the local site investigators at each CPET centre. The third substudy will investigate the role of the 6 min walk test (6MWT) for assessing preoperative functional capacity and predicting postoperative outcome. This simple and inexpensive exercise test may help stratify surgical patients based on their performance on CPET. In a subset of study participants, we will assess the ability of the 6MWT to predict short-term postoperative quality of recovery, medium-to-long term disability after surgery, and performance on CPET.

ETHICS AND DISSEMINATION
The METS Study has received research ethics board approval at all participating sites. The study poses minimal additional risk to study participants. Specifically, all CPET assessments are performed under close medical supervision. In addition, prior data show CPET to be very safe, with major complications occurring in 8–13 per 100000 tests, and death in 2–5 per 100000 tests. It has an established role for assessing patients with cardiopulmonary disease, and can be performed safely in high-risk populations, such as individuals with pulmonary hypertension or small abdominal aortic aneurysms.

The results of the METS Study will be published in peer-reviewed journals, in addition to being presented at national and international conferences. We anticipate these results to be published in 2017, after completion of 1-year follow-up of all recruited participants. We will also liaise with representatives of relevant clinical practice guideline organisations to ensure that the study findings will help inform future recommendations for perioperative care.

CONCLUSIONS
By defining the most accurate approaches for evaluating preoperative cardiopulmonary fitness, the results of the METS Study will help clinicians to better identify high-risk patients who would benefit from preoperative optimisation, interventions, haemodynamic management, closer postoperative surveillance or avoidance of surgery. Furthermore, once patients with poor functional capacity can be more accurately identified, opportunities will arise for randomised controlled trials of interventions to improve their outcomes, such as preoperative exercise training programmes, perioperative haemodynamic optimisation and enhanced postoperative care (eg, hospitalist-surgeon co-management models). Thus, the METS Study has the potential to substantially inform and improve the care of the millions of individuals who undergo major surgery worldwide every year.

Author affiliations
1St. Michael’s Hospital/Toronto General Hospital/University of Toronto, Toronto, Ontario, Canada
2Queen Mary University of London, London, UK
3Alfred Hospital/Monash University, Melbourne, Victoria, Australia
4St. Michael’s Hospital, Toronto, Ontario, Canada
5NHS Grampian, Aberdeen, UK
6University Health Network/Mount Sinai Hospital/University of Toronto, Toronto, Ontario, Canada
7University of Toronto/St. Michael’s Hospital, Toronto, Ontario, Canada
8University Hospital Southampton/University of Southampton, Southampton, UK
9Sunnybrook Health Sciences Centre/University of Toronto, Toronto, Ontario, Canada

Acknowledgements DNW is supported in part by a New Investigator Award from the Canadian Institutes of Health Research. DNW and BHC are supported
in part by Merit Awards from the Department of Anaesthesia at the University of Toronto. RMP is a British Journal of Anaesthesia/Royal College of Anaesthetists Career Development Fellow, and a UK National Institute for Health Research Professor. TEFA is a Medical Research Council and British Journal of Anaesthesia Clinical Research Training Fellow. MPWG holds the British Oxygen Company Chair of Anaesthesia of the Royal College of Anaesthetists, which is awarded by the UK National Institute of Academic Anaesthetists.

**Collaborators**


**Contributors**

DNW, RPM, MAS, TEFA, BLC, JTG, KET, MPWG, PSM and BHC contributed to the conception and design of the study. DNW, RPM, MAS, TEFA, ET, BLC, JTG, KET, MPWG, CF, PSM and BHC contributed to the acquisition, analysis and interpretation of the data. DNW wrote the first draft of the protocol. DNW, RPM, MAS, TEFA, ET, BLC, JTG, KET, MPWG, CF, PSM and BHC Revised the protocol critically for important intellectual content. DNW, RMP, MAS, TEFA, ET, BLC, JTG, KET, MPWG, CF, PSM and BHC revised the protocol critically for important intellectual content. DNW and BHC are the guarantors. All authors have read and approved the final version of the manuscript to be published.

**Funding**

This work was supported by the Canadian Institutes of Health Research (Operating Grant Application Number 528245), Heart and Stroke Foundation of Canada (Grant-in-Aid G-13-000159), Ontario Ministry of Health and Long-Term Care, National Institute of Academic Anaesthetics, UK Clinical Research Network (UKCRN ID 114176), Australian and New Zealand College of Anaesthetists, and Monash University (Melbourne, Victoria, Australia).

**Disclaimer**

These sponsors had no role in the design and conduct of the METS Study; collection, management, analysis and interpretation of the data; preparation, review or approval of this protocol paper; and decision to submit this protocol manuscript for publication.

**Competing interests**

None declared.

**Ethics approval**

The METS Study was approved by the following research ethics boards: St. Michael’s Hospital (Toronto, Ontario, Canada), Sunnybrook Health Sciences Centre (Toronto, Ontario, Canada), South East Coast—Surgery Research Ethics Committee (UK), The Alfred Ethics Committee (Melbourne, Victoria, Australia), Melbourne Health Human Research Ethics Committee (Melbourne, Victoria, Australia), Peter MacCallum Cancer Centre Human Research Ethics Committee (Melbourne, Victoria, Australia), Central Adelaide Local Health Network (Adelaide, South Australia, Australia), Metro South Hospital and Health Service (Brisbane, Queensland, Australia), The Tasmanian Health and Medical Human Research Ethics Committee (Hobart, Tasmania, Australia), Hunter New England Research Ethics Committee (Newcastle, New South Wales, Australia), Northern B Health and Disability Ethics Committee (Wellington, New Zealand).

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**Open Access**

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

**REFERENCES**


Correction


BMJ Open 2016;4:e010359corr1. doi:10.1136/bmjopen-2015-010359corr1